federal_register: 2012-1744

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts regulation_id_numbers
2012-1744 Oral Dosage Form New Animal Drugs; Milbemycin Oxime, Lufenuron, and Praziquantel Rule The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Novartis Animal Health US, Inc. The NADA provides for the veterinary prescription use of milbemycin oxime, lufenuron, and praziquantel for the prevention of heartworm disease, for prevention and control of fleas, and for the treatment and control of various internal parasites in dogs. 2012-01-27 2012 1 https://www.federalregister.gov/documents/2012/01/27/2012-1744/oral-dosage-form-new-animal-drugs-milbemycin-oxime-lufenuron-and-praziquantel https://www.govinfo.gov/content/pkg/FR-2012-01-27/pdf/2012-1744.pdf Health and Human Services Department; Food and Drug Administration 221,199 The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Novartis Animal Health US, Inc. The NADA provides for the veterinary prescription use of milbemycin...  

Links from other tables